Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study

The aim of this study was to determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of bortezomib plus docetaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. Forty-eight patients received up to eight 21-day cycles of docetaxel (60–100 mg m(−2)...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Awada, A, Albanell, J, Canney, P A, Dirix, L Y, Gil, T, Cardoso, F, Gascon, P, Piccart, M J, Baselga, J
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2008
Témata:
Clinical Study
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2391111/
https://ncbi.nlm.nih.gov/pubmed/18454159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604347
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky